AZACYCLIC CONSTRAINED ANALOGS OF FTY720

(19)

(11)

EP 3 022 176 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	25.12.2019 Bulletin 2019/52

(45)	Mention of the grant of the patent:
	11.09.2019 Bulletin 2019/37

(21)	Application number: 14825876.7

(22)	Date of filing: 15.07.2014

(51)

International Patent Classification (IPC):

C07D 207/12^(2006.01)
A61P 35/02^(2006.01)

A61K 31/40^(2006.01)
C07F 9/572^(2006.01)

(86)	International application number:
	PCT/US2014/046711

(87)	International publication number:
	WO 2015/009731 (22.01.2015 Gazette 2015/03)

(54)	AZACYCLIC CONSTRAINED ANALOGS OF FTY720 EINGESCHRÄNKTE AZACYCLISCHE ANALOGA VON FTY720 ANALOGUES AZACYCLIQUES DE FTY720 À STRUCTURE CONTRAINTE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

15.07.2013 US 201361846506 P

(43)	Date of publication of application:
	25.05.2016 Bulletin 2016/21

(73)	Proprietors:
	The Regents of the University of California Oakland, CA 94607-5200 (US) Université de Montréal Montreal, QC H3T 1J4 (CA)

(72)	Inventors:
	EDINGER, Aimee Irvine, CA 92697 (US) HANESSIAN, Stephen Beaconsfield, QC H9W 5H3 (CA)

(74)	Representative: Patentanwaltskanzlei Matschnig & Forsthuber OG
	Biberstraße 22 Postfach 36 1010 Wien 1010 Wien (AT)

(56)

References cited: :

WO-A1-2008/079382
US-A1- 2005 256 056
US-A1- 2010 022 655

WO-A2-2009/106599
US-A1- 2006 019 900

R. ZHU ET. AL.: "Asymmetric Synthesis of Conformationally Constrained Fingolimid Analogues - Discovery of an Orally Active Sphingosine 1-Phosphate Receptor Type-1 Agonist and Receptor Type-3 Antagonist", JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, 11 October 2007 (2007-10-11), pages 6428-6435, XP008108140, DOI: 10.1021/jm7010172
S. HANESSIAN ET. AL.: "Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors.", BIORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 17, 10 October 2006 (2006-10-10), pages 491-494, XP005827260, DOI: 10.1016/j.bmcl.2006.10.014
FRANSSON ET AL.: 'Design, Synthesis, and Antileukemic Activity of Stereochemically Defined Constrained Analogues of FTY720 (Gileny' ACS MED. CHEM. LETT. vol. 4, no. 10, 2013, pages 969 - 973, XP055308249 Retrieved from the Internet: <URL:http://pubs.acs.org/doi/abs/10.1021/m1 4002425> [retrieved on 2014-11-26]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).